- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06261476
Safety of Ashwagandha (Withania Somnifera) Root Extract
Safety of Ashwagandha (Withania Somnifera) Root Extract: An Open-Label, Non-Comparative, Prospective Study in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To qualify for this study, participant must be a healthy male or female between 18 and 65 years old, free from any chronic illness, such as diabetic, cardiovascular, or any other conditions that could affect the safety of the study. Participants must have no plan to commence any other alternative treatment modality for their conditions. Participants must be willing to sign an informed consent document and to comply with all study related procedures.
In this study, 100 subjects will be enrolled at 2 sites, for a total duration of 12 weeks. At the initial visit, prospective patients will be screened for enrollment based on the requirements of the study, medical history, and clinical examination. Before starting any study related procedures, participants will be explained about the study in detail and a written informed consent will be obtained from participants prior to participation in this study. This document is a part of the written informed consent procedure. A detailed medical history including the associated conditions will be recorded. A general and physical examination will be performed to detect any abnormal parameters. If participants meet the eligibility criteria, they will be enrolled in the study.
After enrollment in the study, participants will be assigned to take two capsules of Ashwagandha (500 mg) twice daily after breakfast and dinner with ambient temperature water for 12 weeks. At Visit 1 (Screening/Enrollment/Baseline Visit - Day -3 to Day 0), demography and medical history will be taken, physical examination and vital signs will be performed, blood will be collected, and the study medication will be dispensed.
At Visit 2 (Week 4 ± 4 days) and Visit 3 (Week 8 ± 4 days), participants will return to the site for a followup. A physical examination and vital signs will be performed, blood will be collected, study medication will be dispensed, and compliance will be assessed.
At Visit 4 (Final Visit - Week 12 ± 4 days), physical examination and vital signs will be performed, blood will be collected, Quality of Life will be assessed using the SF-36 QoL scale, and compliance will be assessed. Participants will be monitored throughout the study, including any adverse events. At study completion, participants are required to return any remaining testing products to the San Francisco Research Institute.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94127
- Recruiting
- SF Research Institute
-
Contact:
- John Ademola, PhD
- Phone Number: 415-549-9362
- Email: studyrecruitment@sfinstitute.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Both adults (male and female) aged between 18 and 65 years.
- Participant should be healthy and free from any chronic illness, such as diabetic, cardiovascular or any other condition that could affect the safety of the study.
- No plan to commence any other alternative treatment modality for their conditions.
- Willingness to sign an informed consent document and to comply with all study related procedures.
Exclusion Criteria:
- History of Alcohol or smoking abuse.
- History of hypersensitivity to Ashwagandha.
- Taking nutritional or energy supplements, medication, or steroids.
- Any history of drug abuse.
- Having any clinical abnormalities.
- Simultaneously participating in any other clinical trial or participated in the past three months.
- Participants who use medication for blood pressure, use betablockers, inhaled any beta-agonists, use any hormonal contraceptives, having a history of corticosteroid use within three months, participants under psychotropic medication within last 8 weeks, and
- Participants diagnosed with any heart disease, diabetes, stroke, neurological disorders or depression.
- Have clinically significant acute unstable hepatic, renal, cardiovascular, or respiratory disease that will prevent participation in the study.
- Patients with depressive episode, panic disorder, social phobia, obsessive-compulsory disorder, alcohol dependency; schizophrenia and mania.
- Patients with post traumatic disorder.
- Have an established practice of meditation for three or more months.
- Pregnant and lactating women.
- Participation in other clinical trials during previous 3 months.
- Any clinical condition, according to the investigator which does not allow safe fulfillment of clinical trial protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ashwagandha (Withania somnifera) Root Extract
Participants will take two Ashwagandha capsules containing 500 mg standardized root extract twice daily after breakfast and dinner, for a duration of 12 weeks.
|
Ashwagandha is the active ingredient in Withania somnifera (a medicinal plant in Indian medicine).
Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemoglobin Test
Time Frame: 12 weeks
|
Evaluate the mean change in hemoglobin from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Total Erythrocyte Count
Time Frame: 12 weeks
|
Evaluate the mean change in total erythrocytes from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Total Leukocyte Count
Time Frame: 12 weeks
|
Evaluate the mean change in total leukocytes from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Platelet Count
Time Frame: 12 weeks
|
Evaluate the mean change in platelets from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Hematocrit Test
Time Frame: 12 weeks
|
Evaluate the mean change in hematocrit from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Total Cholesterol Test
Time Frame: 12 weeks
|
Evaluate the mean change in total cholesterol from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
LDL Test
Time Frame: 12 weeks
|
Evaluate the mean change in LDL from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
HDL Test
Time Frame: 12 weeks
|
Evaluate the mean change in HDL from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Triglycerides Test
Time Frame: 12 weeks
|
Evaluate the mean change in triglycerides from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Serum Alkaline Transaminase Test
Time Frame: 12 weeks
|
Evaluate the mean change in serum alkaline transaminase from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Aspartate Transaminase Test
Time Frame: 12 weeks
|
Evaluate the mean change in aspartate transaminase from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Alkaline Phosphatase Test
Time Frame: 12 weeks
|
Evaluate the mean change in Alkaline Phosphatase from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Bilirubin Test
Time Frame: 12 weeks
|
Evaluate the mean change in bilirubin from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Serum Creatinine Test
Time Frame: 12 weeks
|
Evaluate the mean change in serum creatinine from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Blood Urea Nitrogen Test
Time Frame: 12 weeks
|
Evaluate the mean change in blood urea nitrogen from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
T4
Time Frame: 12 weeks
|
Evaluate the mean change in thyroid profile serum thyroxin (T4) from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
T3
Time Frame: 12 weeks
|
Evaluate the mean change in serum triiodothyronine (T3) from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Serum TSH
Time Frame: 12 weeks
|
Evaluate the mean change in serum TSH from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Fasting Blood Sugar
Time Frame: 12 weeks
|
Evaluate the mean change in fasting blood sugar from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
HbA1c
Time Frame: 12 weeks
|
Evaluate the mean change in HbA1c from Visit 1 (Screening/Enrollment/Baseline Visit), Visit 2 (Week 4), Visit 3 (Week 8), and Visit 4 (Week 12), end of study in healthy subjects.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 12 weeks
|
Number and proportion of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse event (TESAE) due to Ashwagandha capsules over 12 weeks
|
12 weeks
|
Quality of Life (SF-36 QoL)
Time Frame: 12 weeks
|
Changes from baseline in the Quality of Life (SF-36 QoL) scores over a period of 12 weeks after start of Ashwagandha
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- DYP-Pharm-RP-23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Ashwagandha (Withnia somnifera)
-
Tatyasaheb Kore Dental CollegeCompletedChronic PeriodontitisIndia
-
Natreon, Inc.CompletedGeneralized Anxiety DisorderIndia
-
Arjuna Natural LimitedKU Leuven; ZB Sports Development BVBAUnknown
-
University of Colorado, Colorado SpringsCompletedStress | Sleep | Craving | Well BeingUnited States
-
Chengappa, K.N. Roy, MDStanley Medical Research Institute; Maryland Psychiatric Research CenterActive, not recruitingSchizophreniaUnited States
-
Blanca Roman-Viñas, MDCompleted
-
National University of Natural MedicineHelfgott Research InstituteCompletedAutoimmune Diseases | Inflammation | CancerUnited States
-
SF Research Institute, Inc.RecruitingSexual HealthUnited States
-
SF Research Institute, Inc.RecruitingSexual HealthUnited States
-
Sunnybrook Health Sciences CentreRecruiting